Abstract
Tumor growth is dependent on angiogenesis.At present,antiangiogenic treatment has been one of the most studied and exploited targets for molecular cancer therapy.Up to date,anti-angiogenesis drugs,which has already been applicated in clinic widely,include bevacizumab,endostar,multi-target tyrosine kinase inhibitor such as sorafenib and sunitinib.The main adverse effects associated with antiangiogenic therapy include hypertension,cardiotoxicity,thrombosis,bleeding,proteinuria,impaired wound healing,gastrointestinal perforation,lassitude,diarrhoea,hand foot shin response,etc,the later three is common in sorafenib and sunitinib.The majority of adverse effects are generally mild to moderate in severity and tolerated by patients.although there are specific,uncommon events that are severe and can be lifethreatening. Key words: Angiogenesis inhibitors; Neoplasms
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
